Actively Recruiting
Axatilimab Compared to Best Available Therapy for Children with Chronic Graft-Versus-Host Disease After Two or More Prior Treatments
Led by Incyte Corporation · Updated on 2026-10-09
60
Participants Needed
41
Research Sites
25 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to compare Axatilimab versus the best available therapy in children aged 2 to under 18 years with chronic graft-versus-host disease cGVHD who have already tried at least two previous systemic treatments. The study focuses on those with moderate to severe active cGVHD requiring ongoing immune suppression, including participants who have had prior stem cell transplants from various donor types and conditioning methods. Participants will be randomly assigned to receive either Axatilimab at a specific dose or a best available therapy selected by the investigator. The best available therapy may include drugs like cyclosporine, tacrolimus, extracorporeal photopheresis, mycophenolate mofetil, mTOR inhibitors, rituximab, imatinib, methotrexate, ibrutinib, or pentostatin, but excludes experimental agents not approved for any indication. Systemic corticosteroids are allowed if the dose is stable. Throughout the study, participants will be monitored for their response to treatment at 6 months and up to 5 years, including quality of life assessments and adverse events. Researchers will measure how well the disease responds, the pharmacokinetics of Axatilimab, reductions in corticosteroid use, and organ-specific effects. The total study duration includes treatment and long-term follow-up to evaluate safety and effectiveness outcomes.
CONDITIONS
Brief Title
A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
Research Team
I
Incyte Corporation Call Center (US)
I
Incyte Corporation Call Center (ex-US)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here